mefloquine + memantine + temozolomide

This is an investigational combination therapy consisting of three repurposed drugs—mefloquine, memantine, and temozolomide—studied primarily for the treatment of newly diagnosed glioblastoma. Mefloquine is an antimalarial agent with proposed anticancer activity through induction of autophagy and apoptosis. Memantine is a non-competitive NMDA receptor antagonist commonly used in Alzheimer's disease, with potential antiproliferative and neuroprotective effects in cancer settings. Temozolomide is an oral alkylating agent that induces DNA damage by methylation, leading to tumor cell death; it is standard-of-care for glioblastoma. The combination aims to leverage multiple mechanisms to enhance antitumor efficacy while maintaining tolerability[1][2][5].